SLU-PP-332

guinea pig

Also seen as: SLUPP332

The Dose Guy’s verdict

Sep 1, 2026
3 sources

The “exercise in a pill” headline was real, in mice. SLU-PP-332 made sedentary rodents run longer, shifted their muscle fibers toward endurance types, and cut fat in obese models. Zero human trials. Zero human safety data. And the compound itself lacks oral bioavailability, which means the capsules being sold are unlikely to deliver much of it to your bloodstream. Striking rodent science, and that is all it is. If you came here for fat loss, semaglutide and tirzepatide are in a different universe of evidence.

Would I take it?Caution, headline outran the evidence.

What it is

A synthetic agonist of the estrogen-related receptors ERR-alpha, ERR-beta, and ERR-gamma, a family of nuclear receptors that regulate the genes exercise normally turns on: mitochondrial biogenesis, fatty acid oxidation, muscle fiber switching. In mice, activating these receptors with SLU-PP-332 triggered the genetic signature of aerobic exercise without the exercise, which is why the press ran with it.

The problem is practical. The mouse work uses intraperitoneal injection, and SLU-PP-332 itself lacks oral bioavailability. It does not reach the bloodstream in useful amounts when taken orally. A follow-on analogue called SLU-PP-915 was built to fix this absorption problem, which tells you the original was never designed to be swallowed. On the weight-loss shelf, every exercise-mimetic compound shares the same gap between the rodent press release and human proof. O-304 has at least reached early human work. SLU-PP-332 has not.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Striking rodent data, one human cell study, zero human trials:

SLU-PP-332 increased type IIa oxidative skeletal muscle fibers and enhanced exercise endurance in mice, through an ERR-alpha-dependent activation of the aerobic exercise genetic program.ACS Chem Biol 2023 · discovery · mice

In diet-induced obese and ob/ob mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, reduced obesity, and improved insulin sensitivity.JPET 2024 · obese mice

In muscle cells from inactive women, SLU-PP-332 reduced cytotoxicity and senescence and promoted myotube formation. That is a dish, not a person.Front Physiol 2025 · primary human myoblasts

No published human trial of SLU-PP-332 for efficacy, safety, dosing, or pharmacokinetics exists.as of Aug 2026

Realistic protocols

I am not building a dosing protocol for a compound with no human data and no oral bioavailability. The vendors selling capsules are selling a headline. Forum doses circulate, loosely, but they are guesswork built on mouse injection data, which is not a starting point for human oral dosing. If you run it anyway, understand that most of it is probably not reaching your bloodstream, and that nobody has measured what it does to a person at any dose.

Side effects

No human side-effect data exists:

unknownZero human safety or tolerability data. The compound was not designed for human oral use, and the people taking it are the entire safety database.

anecdotalNo consistent community reports to draw from. Use is too niche and too recent for a pattern to form.